Condition: Low Rectal Cancer · Sponsor: Sir Run Run Shaw Hospital
This is an open-label, prospective, multicenter phase II clinical trial to evaluate modified short-course radiation (Radiation targeting the tumor bed without irradiating surrounding tumor-draining lymph nodes) combined with CAPOX and PD-1 Inhibitor (Tislelizumab) for patients with MSS middle and low rectal cancer. A total of 32 patients will be enrolled in this trial. The primary endpoint is the rate of pathological complete response (pCR). The organ preservation rate, tumor regression grade, long-term prognosis, and adverse effects will also be analyzed.
This description comes directly from the study's public registry record.
Zhangfa Song, M.D, PH.D · +86 13867421652 · songzhangfa@zju.edu.cn
Cheng Cai, master · +86 18395995912 · ColoSurg_cc@zju.edu.cn
Always discuss trial participation with your own doctor first.
| Sir Run Run Shao hospital | Hanzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05972655